Inquiry Basket
Loading ......
Aspergillus fumigatus is a typical environmental fungus which can lead to various clinical conditions spanning harmless colonization to severe invasive diseases. The major clinical manifestations of Aspergillus infection among non-immunocompromised patients are chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA). Aspergillus specific immunoglobulin G (IgG) humoral responses are essential elements for the diagnosis and treatment of these conditions.
1.1 First Contact and Antigen Capture
1.2 B Cell Activation and Fine Tuning
1.3 Target Spectrum: What IgG Recognizes
1.4 Timing of the IgG Wave
2.1 Chronic Pulmonary Aspergillosis
Elevated Aspergillus specific IgG is detected in > 90% of CPA cases, outperforming precipitins and antigen tests in sensitivity.
Serial IgG measurements correlate with disease trajectory—declining after successful antifungal therapy or surgical resection, and rising with treatment failure or relapse.
2.2 Allergic Bronchopulmonary Aspergillosis
Although total and specific IgE remain core to ABPA diagnosis, elevated IgG can signal concurrent CPA or indicate a more complex immune response when levels exceed those typically seen in pure allergic disease.
In cystic fibrosis–associated ABPA, quantitative IgG thresholds (e.g., 75–90 mg/L) have discriminated sensitized from truly allergic individuals with > 90% accuracy.
3.1 Traditional Precipitin Techniques
3.2 ELISA
Modern ELISA platforms employ whole cell extracts or recombinant antigens to deliver precise, reproducible IgG concentrations within hours. Automated systems minimize operator variability and facilitate longitudinal monitoring in routine practice.
Assays based on conidial and hyphal extracts capture a broad IgG repertoire, enhancing sensitivity for CPA, whereas those using purified or recombinant proteins (e.g., Asp f 1) may improve specificity but risk missing antibodies to other clinically relevant antigens.
4.1 Guiding Antifungal Therapy
As azole resistance emerges, quantitative IgG trends can prompt early phenotypic susceptibility testing when antibody levels fail to decline on therapy.
Defining IgG thresholds for "serological cure" remains under study, but stable low titers coupled with radiological improvement provide a composite marker of successful intervention.
4.2 Vaccine and Therapeutic Antibody Development
Human IgG monoclonal antibodies derived from patients with robust anti–A. fumigatus responses enable identification of immunodominant epitopes for subunit vaccine design.
High affinity IgG clones targeting secreted proteases or polysaccharides may serve as adjunctive therapies in refractory CPA, neutralizing virulence factors and enhancing fungal clearance.
To empower investigations into IgG mediated immunity and diagnostics, we offer:
Aspergillus specific IgG occupies a central role in the modern management of A. fumigatus–related diseases. Quantitative, reproducible IgG assays not only enhance diagnostic accuracy for CPA and ABPA but also guide therapeutic choices and underpin translational research into vaccines and immunotherapies. By providing a comprehensive suite of IgG focused reagents and assays, we aim to accelerate advances in patient care and deepen our understanding of antifungal immunity.
References
| Target | Cat. No. | Product Name | Size | Species | Application | Detection Sample | |
| A. fumigatus | DEIA313 | Human Aspergillus Fumigatus IgA ELISA Kit | 96T | Human | Quantitative | serum, plasma | Inquiry |
| DEIA314 | Human Aspergillus Fumigatus IgM ELISA Kit | 96T | Human | Quantitative | serum, plasma | Inquiry | |
| DEIA312 | Human Aspergillus Fumigatus IgG ELISA Kit | 96T | Human | Quantitative | Serum, plasma | Inquiry |
Loading ......
